Medistep Healthcare IPO
LiveAlready have an account? Apply now
Schedule of Medistep Healthcare
| Issue open date | 08 Aug 2025 |
| Issue close date | 12 Aug 2025 |
| UPI mandate deadline | 12 Aug 2025 (5 PM) |
| Allotment finalization | 13 Aug 2025 |
| Refund initiation | 14 Aug 2025 |
| Share credit | 14 Aug 2025 |
| Listing date | 18 Aug 2025 |
| Mandate end date | 28 Aug 2025 |
| Lock-in end date for anchor investors (50%) | 12 Sep 2025 |
| Lock-in end date for anchor investors (remaining) | 11 Nov 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Medistep Healthcare
Incorporated in 2023, Medistep Healthcare Limited is a pharmaceutical company delivering high-quality healthcare and wellness products. The company operates across both manufacturing and trading verticals, producing sanitary pads and energy powder in-house. Its trading portfolio spans a broad range of pharmaceuticals, nutraceuticals, intimate care, and surgical products, catering to diverse segments within the healthcare industry.
Financials of Medistep Healthcare
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹16.10 crores |
| Fresh Issue | ₹16.10 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility | 0.5 (3.1%) |
| Working capital requirements | 12.34 (76.6%) |
| General corporate purposes |
Strengths
- Diverse product portfolio including traded healthcare goods and in-house brands
- Experienced promoters and leadership with strong domain expertise
- Robust distribution network ensuring wide market penetration and customer retention
- A customer-centric, lean business model built for growth and scalability
- Strategic technology upgrades enhancing production capacity and enabling product diversification
- Positioned to capitalize on high-growth segments in the Indian pharmaceutical, nutraceutical, and sanitary product markets
Risks
- Heavy dependence on Gujarat for revenue generation, exposing the business to regional disruptions
- Reliance on few key clients and suppliers without contracts
- Raw material cost fluctuations may impact financials
- Inability to secure timely and adequate working capital may disrupt operations and hinder growth
- Competitive industry combined with extensive regulatory challenges